Ticagrelor is a cardiovascular medicine used to manage circulation safety. Reducing platelet activity, Ticagrelor helps keep blood flowing through the body's essential vessels.
Ticagrelor belongs to a group of medicines called antiplatelet agents, which help stop blood platelets from clumping together and forming clots. It is the active compound in several ticagrelor medications, including Brilinta, that are used in Australia.
These medicines target a specific step in the clotting process, reducing the chance that a new blockage will develop in the arteries or after a stent placement.
Ticagrelor is commonly used to address:
People who have had these cardiac events or procedures are the typical users of ticagrelor medications.
After the tablet is swallowed, the medicine travels through the bloodstream and reaches the platelets, the tiny cells that normally help stop bleeding. Ticagrelor blocks a receptor on these platelets that tells them to stick together, so the cells remain separate and are less likely to form a blockage.
Women who are pregnant, planning to become pregnant, or who are breastfeeding should discuss alternative options, as the risk of ticagrelor in these situations is not fully established. People with active bleeding, a history of serious bleeding disorders, or severe liver disease also need to be cautious.
Ticagrelor can interact with:
For exact interaction details, always check the labeling that comes with your specific medication.
Older adults, people taking other blood-thinning medicines, and those with a history of bleeding problems tend to notice side effects more often. Individuals with severe kidney or liver impairment may also experience a higher incidence of adverse reactions.
Store ticagrelor tablets in a cool, dry place away from direct sunlight and moisture. Most products are packaged in bottles that keep the tablets protected until the expiration date. Depending on the formulation, treatment may be short-term after a cardiac event or continue for many months to manage long-term risk. Different brands of Brilinta may contain varying strengths or release mechanisms, so always follow the specific directions on your bottle.
For Ticagrelor-specific instructions, refer to the medication information supplied with the product.
Antiplatelet: A type of medicine that helps prevent blood platelets from sticking together to form clots. Platelet aggregation: The process where platelets clump together, which can block blood flow. P2Y12 receptor: A tiny protein on platelets that triggers them to stick together; blocking it reduces clot formation.
This article provides an educational overview of ticagrelor and is not a substitute for professional medical advice. Medicines that contain ticagrelor, such as Brilinta, can differ in formulation, strength, and the directions they carry. The information here does not replace professional clinical judgment. Readers should review their specific medication's labeling and seek guidance from a healthcare professional.
